Boston Scientific Corp (BSX) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Boston Scientific Corp (BSX)

42.68

-0.80 (1.84%)

as of Jun 30, 2026, 8:00:00 pm Market Open.

101 watching

Investor Insights

Jun 30, 2026, 12:00 am

This summary was created by AI, based on 10 opinions in the last 12 months.

Boston Scientific Corp (BSX-N) has been experiencing challenges lately, with a notable decline in stock performance since 2025, breaking critical support levels and exhibiting technical weaknesses as it currently trades below its 200-day moving average. Organic growth has been subpar, as the company recently cut guidance from projected rates, which has contributed to a lack of investor confidence. While the firm is recognized as a leading player in the medical device sector, specifically in non-invasive heart instrumentation, competition has intensified, leading to market share losses against bigger players like Medtronic and Abbott. Despite a strong long-term outlook fueled by aging demographics and increasing demand for cardiovascular procedures, analysts are cautious, recommending a wait-and-see approach as the current valuation appears too high. Overall, Boston Scientific remains a quality organization within its sector, but near-term uncertainties warrant skepticism.

Consensus

Sell

Valuation

Overvalued

Similar

MDT

BUY

BDX vs. TMO

Avoid TMO because their revenues are flattening. Both trade at a high PE. BDX hasn't done much in share movement. He'd rather pay more for Boston Scientific which performs better.

PAST TOP PICK

(A Top Pick Dec 28/22, Up 27%)

Still owns shares. Venture capital fund in health care business. One of most successful funds in biotech. Expecting consistent gains going forward.

HOLD

Above FMV of $40 by 22%. Growth is fairly nice. He thinks it will hold fairly well. A bouncy kind of stock.

DON'T BUY

It is at a new high in terms of price but not new highs in terms of Price/Book. There is no yield and a 25% downside risk.

BUY

It is a leader in the field so the price is at a premium for a good reason. Has had a good bounce. You could also look at MedTech and Thermo-Fisher.

TOP PICK

World's leader in med tech. He's doubling down on US healthcare. Leader in cardio surgical technology. Healthcare, neglected through Covid, will be a very high growth area for the next couple of years. No dividend. (Analysts’ price target is $49.96)

PARTIAL SELL

Can be a safe haven stock. Health care offers defence. But BSX has had a big run and he expects this market to roll over a bit. Take some profits and wait for opportunities, which could mean buying this back in 2-3 months. Has fantastic fundamentals, but valuation is rich.

BUY

Likes it very much. Higher growth. Under pressure post-earnings. Predominantly everything cardiovascular. Covid put off elective surgeries, and these are starting to return. For the rest of 2022, increased volume might offset inflationary pressures.

WAIT

She has owned it for many years and it has not done anything. The COVID scares cast shadows over medical procedure demand. As a medical device provider it has faced head winds. Demand should ramp back up, but it will take confidence by patients to return for procedures.

PAST TOP PICK

(A Top Pick Dec 01/20, Up 22%) Covid delayed surgeries. Labour shortages. Both are holding the stock back, but will improve. Solid, long-term core investment.

HOLD

Holds other healthcare plays. There is a good place for these names in portfolios. The organic growth from resuming treatment and surgeries will be interesting to follow. Wouldn't worry about the pullback.

WAIT

BSX vs. MDT Two great companies. In the implantable medical device business. Loves the area. Too expensive, as investors have flocked to them and the multiple has increased. Would love to own both if prices came down substantially.

BUY

Medical device maker. It has been a bit of a laggard. It was the market darling until 2019 and then they started to have a couple of misses and issues with products. He thinks these are all transient issues. He thinks in 2022 they will grow revenue in high single digits. He is going to stick with it and would buy it here.

PAST TOP PICK

(A Top Pick Dec 01/20, Up 33%) He would buy it again. They had a decade of no-growth. In the last 3-5 years they introduced successful products that got their revenue going again. A lot of their procedures are not necessary today but will be over the next few months. The volumes are coming back. It is at the cheaper end of a lot of healthcare stocks.

BUY ON WEAKNESS

It's one of Abbott's biggest competitors. It's in an attractive industry, medical equipment, where companies earn good returns. But BSX's valuation is high, gotten ahead of itself (like the whole sector), so wait for a pullback. BSX had a strong quarter as non-elective surgeries have bounced back, but its PE is rich.

Showing 16 to 30 of 72 entries

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Bruce Murray

The Murray Wealth Group

Joe Terranova

Virtus Investment Partners

Stephanie Link, Chief investment strategist, Hightower

Hightower

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Boston Scientific Corp (BSX)